arrow
Back
P

Primo N. Lara

University of California, Davis

72H-index
890Paper Count
2.5WCitation Count
Published Papers 126
Publication Date
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non–muscle-invasive bladder cancer
err2026-06-01
err0
errOAAI
errAthira Narayan; Ryan C. Leibrandt; Joyce S. Lee; Marc A. Dall’Era; Jared M. Whitson; Thenappan Chandrasekar; Avery Braun; Matthew Mossanen; Hong Li; Primo N. Lara Jr; Kit S. Lam; Chong-Xian Pan; Mamta Parikh
errShare
errSave
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
err2025-11-01
err0
errOAAI
errParikh, Mamta; Uboha, Nataliya V.; Takebe, Naoko; Tam, Kit; Bedard, Philippe L.; Wisinski, Kari B.; Mittra, Arjun; Yin, Ming; Yang, Yuanquan; Noonan, Anne M.; Holleran, Julianne L.; Ruel, Christopher; Frankel, Paul; Beumer, Jan H.; Newman, Edward M.; Danilov, Alexey V.; Gore, Steven D.; Lara Jr, Primo N.
errShare
errSave
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
err2025-07-07
err0
errOAAI
errAnbarasu Kumaraswamy; Ya-Mei Hu; Joel A. Yates; Chao Zhang; Eva Rodansky; Dhruv Khokhani; Diana Flores; Zhi Duan; Yi Zhang; Shaadi Tabatabaei; Rachel Slottke; Shangyuan Ye; Primo Lara; Adam Foye; Charles J. Ryan; David A. Quigley; Jiaoti Huang; Rahul Aggarwal; Robert E. Reiter; Max S. Wicha; Tomasz M. Beer; Matthew Rettig; Martin Gleave; Christopher P. Evans; Owen N. Witte; Joshua M. Stuart; George V. Thomas; Felix Y. Feng; Eric J. Small; Zheng Xia; Joshi J. Alumkal
errShare
errSave
Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma
err2025-05-01
err0
PREAI
errShuchi Gulati; Lorenzo Nardo; Primo N. Lara
errShare
errSave
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
err2025-02-01
err0
errOAAI
errRiess, Jonathan W.; Lara, Matthew S.; Luxardi, Guillaume; de Rodas, Miguel Lopez; Shimoda, Michiko; Kelly, Karen; Lara, Primo N.; Beckett, Laurel; Monjazeb, Arta; Schalper, Kurt A.; Maverakis, Emanual; Gandara, David R.
errShare
errSave
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis
err2025-01-01
err0
PREAI
errLara, Matthew S.; Riess, Jonathan W.; Kaleka, Guneet; Borowsky, Alexander; McPherson, John D.; Godoy, Luis A.; Grego, Lorenzo; Lara Jr, Primo N.; Mitsiades, Nicholas
errShare
errSave
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216
err2024-11-01
err0
PREAI
errUmang Swami; Yeonjung Jo; Arshit Narang; Melissa Plets; Chadi Hage Chehade; Georges Gebrael; Shilpa Gupta; Zin Myint; Catherine Tangen; Primo N. Lara; Ian M. Thompson; Maha H.A. Hussain; Tanya B. Dorff; Seth P. Lerner; Neeraj Agarwal
errShare
errSave
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
err2024-10-01
err2
errOAAI
errParikh, Mamta; Tangen, Catherine; Hussain, Maha H. A.; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J.; George, Saby; Zibelman, Matthew R.; Cheng, Heather H.; Maughan, Benjamin L.; Zhang, Jingsong; Pachynski, Russell K.; Bryce, Alan H.; Lin, Daniel W.; Quinn, David I.; Lerner, Seth P.; Thompson, Ian M.; Dorff, Tanya B.; Lara, Primo N.; Agarwal, Neeraj
errShare
errSave
Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
err2024-09-01
err0
PREAI
errIngles, S. A.; Pinski, J.; Manojlovic, Z.; Xiong, S.; Weisenberger, D.; Goldkorn, A.; Tangen, C.; McConkey, D.; Lara, P. N.; Hussain, M.; Quinn, D. I.; Thompson, I. M.; Lerner, S.; Dorff, T. B.; Agarwal, N.
errShare
errSave
Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
err2024-09-01
err0
PREAI
errSadeghi, S.; Parikh, R.; Appleman, L. J.; Tsao-Wei, D.; Groshen, S.; Li, M.; Tagawa, S. T.; Nanus, D. M.; Molina, A. M.; Ornstein, M. C.; Rini, B. I.; Dreicer, R.; Quinn, D. I.; Lara, P. N.
errShare
errSave
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
err2024-09-01
err3
PREAI
errLara, Primo N., Jr.; Tangen, Catherine; Heath, Elisabeth I.; Gulati, Shuchi; Stein, Mark N.; Meng, Maxwell; Alva, Ajjai Shivaram; Pal, Sumanta K.; Puzanov, Igor; Clark, Joseph I.; Choueiri, Toni K.; Agarwal, Neeraj; Uzzo, Robert; Haas, Naomi B.; Synold, Timothy W.; Plets, Melissa; Vaishampayan, Ulka N.; Shuch, Brian M.; Lerner, Seth; Thompson, Ian M., Jr.; Ryan, Christopher W.
errShare
errSave
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
err2024-07-25
err1
errOAAI
errLara Jr, Primo N.; Villanueva, Luis; Ibanez, Carolina; Erman, Mustafa; Lee, Jae Lyun; Heinrich, Daniel; Lipatov, Oleg Nikolaevich; Gedye, Craig; Gokmen, Erhan; Acevedo, Alejandro; Semenov, Andrey; Park, Se Hoon; Gafanov, Rustem Airatovich; Kose, Fatih; Jones, Mark; Du, Xiaoqi; Munteanu, Mihaela; Perini, Rodolfo; Choueiri, Toni K.; Motzer, Robert J.
errShare
errSave
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
err2024-07-16
err0
PREAI
errTripathi, Abhishek; Tangen, Catherine M.; Plets, Melissa; Li, Xiaochen; Tretiakova, Maria; Humphrey, Peter A.; Adeniran, Adebowale; Barata, Pedro C.; Gulati, Shuchi; Bergerot, Cristiane D.; Pruthi, Deepak K.; Thompson, Ian M.; Lara, Primo N.; Lerner, Seth P.; Pal, Sumanta K.; Shuch, Brian M.
errShare
errSave
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
err2024-02-29
err0
PREAI
errLara Jr, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; LeBlanc, Michael; Thompson, Ian; Agarwal, Neeraj
errShare
errSave
Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines
err2024-02-01
err23
PREAI
errMotzer, Robert J.; Jonasch, Eric; Agarwal, Neeraj; Alva, Ajjai; Bagshaw, Hilary; Baine, Michael; Beckermann, Kathryn; Carlo, Maria I.; Choueiri, Toni K.; Costello, Brian A.; Derweesh, Ithaar H.; Desai, Arpita; Ged, Yasser; George, Saby; Gore, John L.; Gunn, Andrew; Haas, Naomi; Johnson, Michael; Kapur, Payal; King, Jennifer; Kyriakopoulos, Christos; Lam, Elaine T.; Lara, Primo N.; Lau, Clayton; Lewis, Bryan; Madoff, David C.; Manley, Brandon; Michaelson, M. Dror; Mortazavi, Amir; Ponsky, Lee; Ramalingam, Sundhar; Shuch, Brian; Smith, Zachary L.; Sosman, Jeffrey; Sweis, Randy; Zibelman, Matthew; Schonfeld, Ryan; Stein, MaryElizabeth; Gurski, Lisa A.
errShare
errSave
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
err2024-02-01
err6
errOAAI
errLara, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; Leblanc, Michael; Vogelzang, Nicholas J.; Thompson, Ian; Agarwal, Neeraj
errShare
errSave
Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer
err2023-10-01
err5
errOAAI
errChen, Yixin; Tu, Mei-Juan; Han, Fangwei; Liu, Zhenzhen; Batra, Neelu; Lara, Primo N.; Chen, Hong -Wu; Bi, Huichang; Yu, Ai -Ming
errShare
errSave
Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
err2023-10-01
err0
errOAAI
errLara, P. N.; Tangen, C.; Heath, E.; Stein, M.; Meng, M.; Alva, A.; Pal, S. K.; Puzanov, I.; Clark, J.; Choueiri, T. K.; Agarwal, N.; Uzzo, R.; Haas, N. B.; Plets, M.; Vaishampayan, U. N.; Shuch, B.; Thompson, I. M.; Ryan, C. W.
errShare
errSave
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
errLANCET
IF88.5
err2023-09-01
err21
errOAAI
errRyan, Christopher W.; Tangen, Catherine M.; Heath, Elisabeth, I; Stein, Mark N.; Meng, Maxwell, V; Alva, Ajjai S.; Pal, Sumanta K.; Puzanov, Igor; Clark, Joseph, I; Choueiri, Toni K.; Agarwal, Neeraj; Uzzo, Robert G.; Haas, Naomi B.; Synold, Timothy W.; Plets, Melissa; Vaishampayan, Ulka N.; Shuch, Brian M.; Thompson Jr, Ian M.; Lara Jr, Primo N.
errShare
errSave